Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag in chronic immune thrombocytopenia
NCT01438840Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of avatrombopag in immune thrombocytopenia (ITP) (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Number of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L During 6-Month Treatment Period. Started Feb 2012; status: completed.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01438840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01438840.